

609185

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

APPLICATION FOR A STANDARD PATENT

Eli Lilly and Company, a corporation organised and existing under the laws of the State of Indiana, of Lilly Corporate Center, Indianapolis, Indiana, 46285, UNITED STATES OF AMERICA, hereby apply for the grant of a standard patent for an invention entitled:

Improvements in or Relating to Specific 5-HT3 Antagonists

which is described in the accompanying complete specification.

Details of basic application(s):-

<u>Basic Applic. No:</u>	<u>Country:</u>	<u>Application Date:</u>
094360	US	8 September 1987

The address for service is:-

Spruson & Ferguson
Patent Attorneys
Level 33 St Martins Tower
31 Market Street
Sydney New South Wales Australia

DATED this SIXTH day of SEPTEMBER 1988

Eli Lilly and Company

By: *[Signature]*

Registered Patent Attorney

TO: THE COMMISSIONER OF PATENTS
OUR REF: 66913
S&F CODE: 53710

APPLICATION ACCEPTED AND AMENDMENTS

5845/2

ALLOWED 30.1.91

RECEIVED 06/09/88

CASE: X-6833A

SPRUSON & FERGUSON

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

DECLARATION IN SUPPORT OF A
CONVENTION APPLICATION FOR A PATENT

In support of the Convention Application made for a patent for an invention entitled:
IMPROVEMENTS IN OR RELATING TO SPECIFIC 5-HT₃ ANTAGONISTS
I, Mary Ann Tucker, Lilly Corporate Center, City of Indianapolis, State of Indiana 46285, United States of America do solemnly and sincerely declare as follows:

1. I am authorized by ELI LILLY AND COMPANY the applicant for the patent to make this declaration on its behalf.
2. The basic application as defined by Section 141 of the Act was/~~were~~ made in United States of America

on 08 September 1987

by Marlene Lois Cohen and William Bryant Lacefield

3. Marlene Lois Cohen and William Bryant Lacefield of 521 Oakwood Drive, Indianapolis, Indiana 46260 and 636 Boulder Road, Indianapolis, Indiana 46217 ~~respectively~~ both in the United States of America respectively are the actual inventors of the invention and the facts upon which the applicant is entitled to make the application are as follows:


The said applicant is the assignee of the actual inventors.

4. The basic application(s) referred to in paragraph 2 of this Declaration was/~~were~~ the first application(s) made in a Convention country in respect of the invention(s) the subject of the said application.

DECLARED at Indianapolis, Indiana
this 22ND day of July, 1988

ELI LILLY AND COMPANY

By


Mary Ann Tucker
Assistant Patent Counsel

TO: THE COMMISSIONER OF PATENTS
AUSTRALIA

(12) PATENT ABRIDGMENT (11) Document No. AU-B-21916/88
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 609185

(54) Title
IMPROVEMENTS IN OR RELATING TO SPECIFIC 5-HT₃ ANTAGONISTS

International Patent Classification(s)
(51)⁴ C07D 333/54 A61K 031/54 A61K 031/55 C07D 307/79
C07D 311/58 C07D 451/04 C07D 451/12 C07D 453/02
C07D 498/08 C07D 513/08 A61K 031/445 A61K 031/535

(21) Application No. : 21916/88 (22) Application Date : 06.09.88

(30) Priority Data

(31) Number (32) Date (33) Country
094360 08.09.87 US UNITED STATES OF AMERICA

(43) Publication Date : 09.03.89

(44) Publication Date of Accepted Application : 26.04.91

(71) Applicant(s)
ELI LILLY AND COMPANY


(72) Inventor(s)
MARLENE LOIS COHEN; WILLIAM BRYANT LACEFIELD

(74) Attorney or Agent
SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001

(56) Prior Art Documents
AU 76190/87 C07D 453/02, 453/06, 487/08
AU 46081/89 C07D 498/08, 513/08, A61K 031/54
WO 03281/84

(57) Claim

1. A compound of the Formula I



or a pharmaceutically acceptable salt thereof;

wherein:

R_a and R_b are independently ~~hydrogen~~, methyl, or ethyl, or when taken together with the carbon atom to which they are attached form a C₃-C₆ cycloalkyl ring; ~~provided that R_a and R_b may not both be hydrogen at the same time;~~

(11) AU-B-21916/88
(10) 609185

-2-

E is O, NH, or S;


R_1 and R_{1a} are independently hydrogen, methyl, halo, C_1 - C_3 alkoxy, $(C_1$ - C_3 alkyl)- $S(O)_t$ -, trifluoromethyl, amino, hydroxy, $(CH_3)_2NSO_2$ -, or $(C_1$ - C_3 alkyl)CONH-;

m is 1 or 2;

t is 0, 1, or 2;

Z is O or NH; and

R_2 is quinuclidine, quinuclidine N-oxide, 1-azabicyclo[3.3.1]non-4-yl,




R_{2a}



R_{2b}

or



R_{2c}

wherein

R_3 is C_1 - C_3 alkyl, p and q are independently 0-2; Q is O or S; n is 0 or 1; one of R_4 and R_5 when n is 0 is C_1 - C_4 alkoxy, C_1 - C_4 alkoxy carbonyl, hydroxy, or C_1 - C_4 alkyl optionally substituted by hydroxy, C_1 - C_4 alkoxy, or C_1 - C_4 acyloxy and the other of R_4 and R_5 is hydrogen or C_1 - C_4 alkyl; one of R_4 , R_5 , and R_6 when n is 1 is C_1 - C_4 alkyl and the other two of R_4 , R_5 , and R_6 are independently hydrogen or C_1 - C_4 alkyl.

5. A pharmaceutical formulation for blocking the M-receptors for 5-hydroxytryptamine comprising a compound of Formula I, or a

(11) AU-B-21916/88
(10) 609185

-3-

pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, in association with one or more pharmaceutically acceptable carriers, diluents, excipients and/or adjuvants therefor.

14. A method of treating migraine, emesis, gastrointestinal disorders, schizophrenia, and/or anxiety in a mammal requiring such treatment, comprising administering to said mammal a compound of any one of claims 1 to 4, 7 to 9 or a formulation of any one of claims 5, 11 or 12 in an amount which effectively blocks M-receptors for 5-hydroxytryptamine in said mammal.

S & F Ref: 66913

FORM 10

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

609185

COMPLETE SPECIFICATION

(ORIGINAL)

FOR OFFICE USE:

Class Int Class

Complete Specification Lodged:
Accepted:
Published:

This document contains the
amendments made under
Section 49 and is correct for
printing.

Priority:

Related Art:

Name and Address
of Applicant:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis Indiana 46285
UNITED STATES OF AMERICA

Address for Service: Spruson & Ferguson, Patent Attorneys
Level 33 St Martins Tower, 31 Market Street
Sydney, New South Wales, 2000, Australia

Complete Specification for the invention entitled:

Improvements in or Relating to Specific 5-HT₃ Antagonists

The following statement is a full description of this invention, including the best method of performing it known to me/us

IMPROVEMENTS IN OR RELATING TO
SPECIFIC 5-HT₃ ANTAGONISTS

5

This invention relates to novel bicyclic esters and amides useful as specific 5-HT₃ antagonists.


10

A variety of agents are presently under development as potential treatments for migraine headaches. For example, MDL-72222 (tropine 3,5-dichlorobenzoate) is reported to block the M-receptors for 5-hydroxytryptamine (5-HT), now referred to as 5-HT₃ receptors, thereby providing an antimigraine effect -- see Bradley, et al., Neuropharmacology, 25(6), 563 (1986). Other 5-HT₃ antagonists reported in the literature include Beecham compound 112-574, included in European Patent Application No. 158,265, and Merrell-Toraude compound 105-834, (U.S. Patent No. 4,486,441). All of these compounds are tropine or tropine-like esters or amides of a substituted benzoic acid.

15
20

According to the present invention there are provided compounds of the Formula I

5



10 and pharmaceutically acceptable salts thereof;

wherein

15 R_a and R_b are independently ~~hydrogen~~, methyl, or ethyl, or when taken together with the carbon atom to which they are attached form a C_3 - C_6 cycloalkyl ring, ~~provided that R_a and R_b may not both be hydrogen at the same time;~~

E is O, NH, or S;

20 R_1 and R_{1a} are independently hydrogen, methyl, halo, C_1 - C_3 alkoxy, $(C_1$ - C_3 alkyl)- $S(O)_t$ -, trifluoromethyl, amino, hydroxy, $(CH_3)_2NSO_2$ -, or $(C_1$ - C_4 alkyl)CONH-;

m is 1 or 2;


t is 0, 1, or 2;

Z is O or NH; and




R_2 is quinuclidine, quinuclidine N-oxide,
1-azabicyclo[3.3.1]non-4-yl,

5


 R_2a

10

 R_2b

or

15

 R_2c


wherein

R_3 is C_1 - C_3 alkyl, p and q are independently
 20 0-2; Q is O or S; n is 0 or 1; one of R_4 and R_5 when
 n is 0 is C_1 - C_4 alkoxy, C_1 - C_4 alkoxy carbonyl, hydroxy,
 or C_1 - C_4 alkyl optionally substituted by hydroxy, C_1 - C_4
 alkoxy, or C_1 - C_4 acyloxy and the other of R_4 and R_5 is
 hydrogen or C_1 - C_4 alkyl; one of R_4 , R_5 , and R_6 when n
 25 is 1 is C_1 - C_4 alkyl and the other two of R_4 , R_5 , and R_6
 are independently hydrogen or C_1 - C_4 alkyl.

Many of the functionalities and substituents part of R_2 are similarly provided in WO 84/03281 and the definitions of the substituents as presently employed, to the extent consistent in scope with that found in the reference, are considered to be identical as reported therein.

The term " C_3 - C_6 cycloalkyl ring" refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term " C_1 - C_3 alkoxy" refers to methoxy, ethoxy, propoxy, or isopropoxy. The term " C_1 - C_4 alkyl" refers to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl and includes within its definition the term " C_1 - C_3 alkyl". The term "halo" includes fluoro, chloro, and bromo.

The preferred compounds of this invention are those of Formula Ia



wherein

m is 1 or 2, R_1' is hydrogen, methyl, fluoro, bromo, or especially chloro, R_2' is a tropane ring, i.e., an endo (or 3α) 8-methyl-8-azabicyclo[3.2.1]oct-3-yl group, quinuclidine, i.e., 1-azabicyclo[2.2.2]oct-3-yl, or endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl, and pharmaceutically acceptable salts thereof.


The pharmaceutically acceptable salts of this invention include addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulfuric, or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example glycolic, maleic, hydroxy-maleic, malic, tartaric, citric, lactic, and the like, or organic sulfonic acids, for example, methanesulfonic, ethanesulfonic, p-toluenesulfonic, or naphthalene-2-sulfonic acids. In addition to the pharmaceutically acceptable salts listed above, other acid addition salts, such as those obtained with picric or oxalic acid, may serve as intermediates useful in the ^{preparation} ~~purification~~ of the compounds of this invention or in the preparation of other, for example, pharmaceutically acceptable salts. In addition, these salts may also be useful for identification or characterization of the compounds of this invention.

Also contemplated within the scope of the present invention are hydrates of the compounds or their various salts, or other solvates, such as that formed with ethanol or other non-toxic solvents.

It is appreciated that when R_a and R_b are different, or when R_4 , R_5 or R_6 are other than hydrogen, various stereoisomers are possible. Similarly, the R_2 ring may be in the α - or β - position. This invention includes all individual isomers and the various mixtures thereof.



Intermediates in the preparation of compounds of the invention are aryl carboxylic acid compounds of the Formula IIa




wherein

10 m is 1 or 2;

E is O, NH or S, and R₁ is hydrogen, methyl, halo, trifluoromethyl, (C₁-C₃ alkyl)-S(O)_t⁻, or methoxy. These compounds are useful for preparing many of compounds of Formula I as demonstrated below.

15 According to a second aspect of the invention there is provided a process for preparing the compounds of Formula I as defined above, which comprises:

(a) reacting a compound of the Formula II




wherein X is OH or a carboxylic acid activating group and R₁, R_{1a},

25 R_a, R_b, E, and m are as defined above, with a compound of the Formula III




30 wherein Z and R₂ are as defined above, or

(b) hydrogenating a nitro compound of the Formula




wherein R_1 , R_2 , R_a , R_b , E, Z, and m are as defined above to give a compound of Formula I where R_{1a} is amino, or

(c) halogenating a compound of the Formula




10 where R_1 , R_2 , R_a , R_b , E, Z, and m are as defined above to provide a compound of Formula I where R_{1a} is halo, or

(d) reacting an alkoxy compound of the Formula




20 where R_1 , R_2 , R_a , R_b , E, Z, and m are as defined above, with dealkylating reagent to provide a compound of Formula I where R_{1a} is hydroxy, or

(e) reacting a compound of the Formula



30 where R_1 , R_2 , R_a , R_b , E, Z, and m are as defined above, with dimethylamine to provide a compound of Formula I where R_{1a} is $(\text{CH}_3)_2\text{NSO}_2^-$, or


(f) reacting a compound of the Formula



where R_1 , R_{1a} , R_a , R_b , E , Z , and m are as defined above, and R_2 is R_{2a} , R_{2b} , or R_{2c} and R_3 is hydrogen, with a C_1 - C_3 alkyl halide, or

(g) reacting a compound of the Formula

5




10 where R_1 , R_2 , R_a , R_b , E , Z , and m are as defined above, with an oxidizing agent, and

(h) optionally converting the resulting product into a pharmaceutically acceptable salt.

The compounds of the present invention can be prepared according to

15 Scheme 1

Scheme 1



20

where X is OH or a carboxylic acid activating group such as chloro, bromo, C_1 - C_4 acyloxy (a mixed anhydride), and the like.

25




The reaction between II, where X is an activating group, and III is well known in the art as demonstrated in U.S. Patent No. 4,486,441, EPO Patent Application No. 158,265, and WO 84/03281. Preferably, the carboxylic acid (II, X is OH) is converted to the corresponding acid chloride (II, X is -Cl) upon treatment with an excess of a reagent such as thionyl chloride. When thionyl chloride is employed, it is preferably used both as the reagent and as solvent. The reaction mixture is usually heated at reflux for 1-3 hours to bring the reaction to completion. The resulting acid chloride is then treated with the appropriate amine or alcohol III. Usually, a 1- to 2-fold molar excess of III is employed. In addition, an inert solvent, such as toluene, is preferably used as a more convenient means of allowing the reaction to proceed. When a solvent is used, the mixture is preferably heated at reflux and under an inert atmosphere to drive the reaction to completion. Other variations of this process, including different concentrations, molar proportions, solvents, etc. will be apparent to those skilled in the art. For example, one may employ peptide coupling reagents, such as 1,1'-carbonyldiimidazole, with the carboxylic acid of Formula II, followed by introduction of III to the reaction mixture.

The general chemistry for preparing intermediates II and III is well known in the art. In particular, many of the amines of Formula III are employed in WO 84/03281. These and other necessary intermediates

are either commercially available, known in the literature, or can be prepared by methods known in the art.

In addition, the preparation of intermediates II is similar to that taught in WO 84/03281. The preferred method of preparing the 2,2-dimethyl 6.5 bicyclic compounds is provided in Scheme 2 which follows.

Scheme 2



wherein

one of G and Y is O and the other is S, and E'' is O or NH.

Accordingly to Scheme II, the phenol or aniline of Formula IV is alkylated with 2-methyl-2-propenyl bromide or chloride to provide intermediate V. This transformation is usually accomplished by heating near equimolar amounts of the two reagents together with an acid scavenger, such as potassium carbonate, and an inert solvent, such as acetone, at temperatures from about ambient temperature up to the reflux temperature of the reaction mixture. The alkylated intermediate V is then subjected to a Claisen rearrangement to provide

the phenol or aniline of Formula VI. This rearrangement is accomplished by heating V to temperatures of about 150-200°C, preferably in a non-reactive solvent such as 1-methyl-2-pyrrolidinone.

5 ~~of this invention~~ ^{intermediates,} In order to prepare the dihydrobenzothiophenes intermediate VI ($E'' = O$) is treated with dimethylthiocarbamoyl chloride to provide VII ($G = O$; $Y = S$). This transformation involves a standard acylating procedure which commonly uses a strong base,
10 such as sodium hydride, and a non-reactive solvent, such as dimethylformamide. When heated neat at 220-230°C for approximately 10 minutes, this thionic acid derivative rearranges to provide the corresponding thiolic intermediate VII ($G = S$; $Y = O$) which, upon treatment with
15 base, such as sodium hydroxide, provides the free thiol derivative VIII ($E = S$). This hydrolysis potentially also hydrolyzes the ester which can be reesterified by conventional means. Alternatively, the acid analogue of VIII ($E = S$) may be used for the subsequent cyclization.

20 The conversion of VIII to the bicyclic ester II ($X = OCH_3$) can be accomplished by heating with 90% formic acid at reflux temperatures for 2-3 hours. As mentioned above, in the special case where E is S, the transformation can be accomplished either on the carboxylic acid or ester upon treatment with an alcohol, such
25 as methanol or ethanol, which is saturated with hydrogen chloride gas. This transformation not only results in ring closure, but also reesterifies the free acid. This latter transformation is most efficient when the reaction mixture is allowed to reflux for 16-20 hours.
30



Alternatively, the intermediate of Formula VIII can be treated with hydrogen bromide in a non-reactive solvent such as chloroform to prepare the corresponding alkyl bromide intermediate which can be isolated or used in situ to prepare II (X=OH) upon treatment with alcoholic sodium or potassium hydroxide. See, e.g., U.S. Patent No. 3,860,619.

The esters of Formula II are transformed into the carboxylic acid intermediates (II, X=OH) by standard methods of hydrolysis. Typically, the treatment of the ester with an aqueous solution of an inorganic base, such as potassium or sodium hydroxide, is sufficient to convert the ester to the free acid when allowed to reflux for 2-3 hours. Other methods of effecting this transformation are readily apparent to those skilled in the art.

The related 6.6 bicyclic systems and alkyl variations of R_a and R_b can be prepared by methods analogous to that taught in Scheme 2 above employing the appropriate starting materials, by other means such as are described below, or are provided in the art, such as WO 84/03281.

Other transformations and intraconversions of the compounds ~~of this invention~~ can be accomplished. For example, amino groups may be introduced onto the benzene portion of the bicyclic moiety either as intermediates such as Formulas II and IIa or final products of Formula I. Typically, one or two nitro groups are introduced by direct nitration of the intermediate or final product employing a mixture of nitric and sulfuric



acids. The transformation of a nitro group into an amine is readily accomplished by hydrogenation, for example, in the presence of a 5% palladium-on-carbon catalyst in a non-reactive solvent such as ethyl acetate. One or two nitro groups may be introduced either at the same time or sequentially, i.e., a second nitro group may be introduced after the first has been transformed into the amine.

Halo groups may also be directly introduced at the intermediate or final product stage. Typically, this can be accomplished by treating the intermediate or final product with a halogenating reagent such as iodobenzene dichloride in pyridine or some like halogenating reagent. In like manner, a halogen group can be removed from an intermediate or final product to form the comparable hydrogen-substituted derivative. This is best accomplished by subjecting the intermediate or final product to hydrogenation conditions.

Other transformations and interconversions will be apparent to one skilled in the art. For example, hydroxy-substituted compounds can be prepared from the corresponding alkoxy, particularly the methoxy, substituted intermediates or final products by dealkylating with an appropriate reagent. A preferred such reagent is the use of molten pyridine hydrochloride which is very effective for effecting this transformation. In like manner, an N,N-dimethylsulfonamido group can be introduced onto the benzene ring of the bicycle by treating the precursor intermediate or final product with chlorosulfonic acid in an inert solvent such as

ethylene dichloride at low temperature followed by treatment with dimethylamine. As will be appreciated by the skilled artisan, the particular sequence for effecting such transformations can be determined
5 depending upon the particular substituent and position of the substituent desired.

One additional transformation involves the use of a blocking group on the R_2 portion of the molecule which can be removed and the resulting secondary amino
10 group realkylated to provide a compound of the present invention. For example, those R_{2a} , R_{2b} , and R_{2c} analogues wherein R_3 is benzyl can be introduced into the final product to provide the corresponding N-benzyl cognate. The N-benzyl group may be removed by standard
15 means, such as by subjecting the intermediate to hydrogenation conditions. The resulting secondary amine can then be alkylated with the appropriate C_1 - C_4 alkyl halide in an inert solvent such as tetrahydrofuran or isopropyl alcohol, optionally in the presence of an acid
20 scavenger such as sodium carbonate. Other such blocking groups and means for deblocking will be apparent to those skilled in this art.

The thio derivatives and intermediates ~~of this invention~~ (t is 0) may be transformed into the
25 corresponding sulfoxide (t is 1) compounds upon treatment with a mild oxidizing agent, such as hydrogen peroxide in methanol, meta-chloroperbenzoic acid (MCPBA) in methylene chloride at 0°C ., or an alkali metal periodate in aqueous alcohol. The corresponding
30 sulfones (t is 2) are prepared from the thio or sulfoxide compounds on treatment with a strong oxidizing




agent such as hydrogen peroxide in acetic acid or m-chloroperbenzoic acid in methylene chloride at 20-30°C.

Intermediates IV, and other reagents necessary for preparing intermediates and the compounds of this invention, are commercially available, are known in the literature, or can be prepared by known methods. In addition, those skilled in the art will recognize that variations on the methods for preparing intermediates and the claimed compounds as described above may be performed without detracting from the synthesis of these compounds. For example, other esters may be employed, as may protecting groups, precursors, the direct introduction of the carboxylic acid group onto the phenyl ring of the bicycle (Kolbe-Schmitt reaction) etc. Moreover, certain R₁ substituents may be introduced directly onto the phenyl ring. For example, a chloro group can be introduced by treating with iodobenzene, chlorine, and pyridine (see Murakami et al., Chem. Pharm. Bull. 19, 1696 (1971) or N-chlorosuccinimide in dimethylformamide (U.S. Patent 4,623,657).

The spirocycloalkyl intermediates can be prepared in a number of ways, such as that provided in Scheme 3:

Scheme 3



where w is 1-4. This procedure is generally described in U.S. Patent 4,329,459 which is incorporated herein by reference. The reaction is a double grignard




synthesis and introduces the spiro ring onto the bicyclic nucleus. The intermediate XI can then be carboxylated as described earlier.

In the special case of $w=1$ (the spirocyclopropyl compounds), the ketone of formula IX can be transformed into the corresponding exomethylene compound by any of a variety of procedures, such as the titanium-aluminum complex method of Pine, et al., *J.A.C.S.*, 102(9), 3270 (1980). This exomethylene derivative can then be converted into the spirocyclopropyl compound by treatment with diiodomethane and zinc-copper by the procedure of Simmons and Smith, *J.A.C.S.*, 81, 4256 (1959). See also *Organic Reactions*, 20, Chapter 1, page 109.

The tricyclic compounds of formula XI can also be prepared according to U.S. Patent 4,623,657, or obvious variations thereof. An illustrative example employing the chemistry of this reference is provided in Scheme 4.

Scheme 4



The following examples further illustrate the preparation of ~~the~~ intermediates and ^{the} compounds of this invention. The examples are illustrative only and are not intended to limit the scope of the invention in any way. Where structures were confirmed by infrared, proton nuclear magnetic resonance, or mass spectral analysis, the compound is so designated by "IR", "NMR", or "MS", respectively.

10

Example 1

2,2-dimethyl-2,3-dihydrobenzothiophene-7-carboxylic acid

15 A. Preparation of 2-(2-methyl-2-propenyloxy)-benzoic acid, methyl ester.

A mixture of 152 g of methyl salicylate, 99 g of 3-chloro-2-methylpropene, 151.8 g of potassium carbonate, and 500 ml of acetone was heated at reflux overnight. After cooling, the mixture was extracted with diethyl ether and ethyl acetate. The organic extracts were combined, washed twice with a 10% sodium chloride solution and water, dried over sodium sulfate, and concentrated in vacuo. The resulting liquid was vacuumed distilled. The fraction collected at 120-121°C and 1.5 torr provided 76.2 g of the desired subtitle intermediate. NMR, MS.



Analysis for $C_{12}H_{14}O_3$:

Calc.: C, 69.89; H, 6.84;

Found: C, 70.02; H, 6.93.

5 B. Preparation of 2-hydroxy-3-(2-methyl-2-propenyl)benzoic acid, methyl ester.

A solution of 76.2 g of the intermediate of Example 1A above was heated at reflux for 6 hours in 150 ml of 1-methyl-2-pyrrolidinone. The mixture was then vacuum distilled and the fraction collected at 10 104-109°C and 1.2 torr provided 60.6 g of the desired subtitle intermediate. MS.

Analysis for $C_{12}H_{14}O_3$:

Calc.: C, 69.89; H, 6.84;

Found: C, 69.87; H, 6.89.

15 C. Preparation of 2-[dimethylamino(thioxomethyl)oxy]-3-(2-methyl-2-propenyl)benzoic acid, methyl ester.

To 1 liter of dry dimethylformamide were added 16 g of 60% sodium hydride in oil. After stirring under a nitrogen atmosphere, 81.7 g of 2-hydroxy-3-(2-methyl-2-propenyl)benzoic acid, methyl ester, as a solution in dimethylformamide, were added in dropwise fashion. After stirring at room temperature, a solution 49.6 g of dimethylthiocarbamoyl chloride in dimethylformamide was 20 added over a one hour period. The reaction mixture was stirred at room temperature overnight, then poured onto ice and extracted with diethyl ether and ethyl acetate. 25 The combined organic extracts were washed successively

with a 10% sodium hydroxide solution and water, dried over sodium sulfate, and concentrated in vacuo. The residue was vacuum distilled, and the fraction distilling at 162-168°C and 0.6 torr provided 69.9 g of the
5 desired subtitle intermediate. NMR, MS.

Analysis for $C_{15}H_{19}NO_3S$:

Calc.: C, 61.41; H, 6.53; N, 4.77;

Found: C, 64.87; H, 7.45; N, 4.37.

D. Preparation of 2-[(dimethylamino)carbonyl-
10 thio]-3-(2-methyl-2-propenyl)benzoic acid, methyl ester.

The intermediate from Example 1C above (69.5 g) was heated to 220-230°C for 10-15 minutes. After cooling, the residue was vacuum distilled. The fraction collected at 153-155°C and 0.1 torr and the
15 remaining distillation residue were combined and purified by high pressure liquid chromatography over silica gel eluting with 20% ethyl acetate in toluene. The appropriate fractions were combined and concentrated in vacuo to provide 41.8 g of the desired subtitle interme-
20 diate. MS, IR, NMR.

Analysis for $C_{15}H_{19}NO_3S$:

Calc.: C, 61.41; H, 6.53; N, 4.77;

Found: C, 61.40; H, 6.30; N, 5.05.

E. Preparation of 2-mercapto-3-(2-methyl-2-
25 propenyl)benzoic acid.

The 41.8 g of intermediate from Example 1D above were heated at reflux for 18 hours with 175 ml of methanol and 12 g of sodium hydroxide. The reaction

mixture was poured into ice water and extracted with ethyl acetate. The aqueous layer was made acidic with hydrochloric acid and extracted again with ethyl acetate. The organic layer was washed with water, dried
5 over sodium sulfate, and concentrated in vacuo providing 28.8 g of desired subtitle intermediate, m.p. 89-92°C. NMR, MS.

Analysis for $C_{11}H_{12}O_2S$:

Calc.: C, 63.43; H, 5.81;

10 Found: C, 63.69; H, 5.89.

F. Preparation of 2,2-dimethyl-2,3-dihydro-benzothiophene-7-carboxylic acid, methyl ester.

A mixture of 23.8 g of the intermediate from Example 1E above and 1 liter of methanol was saturated
15 with hydrogen chloride gas and then refluxed overnight. The solution was concentrated in vacuo, added to water, and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and concentrated in vacuo, providing 24.1 g of the desired
20 subtitle intermediate as an oil. MS.

Analysis for $C_{12}H_{14}O_2S$:

Calc.: C, 64.83; H, 6.35;

Found: C, 64.56; H, 6.33.

G. Preparation of 2,2-dimethyl-2,3-dihydro-
25 benzothiophene-7-carboxylic acid.

The 24.1 g of ester product from Example 1F above were heated at reflux with 50 g of sodium hydroxide and 200 ml of water for 2-3 hours. After

cooling, the mixture was extracted with diethyl ether and ethyl acetate. The aqueous layer was acidified with hydrochloric acid and again extracted with ethyl acetate and diethyl ether. These latter organic extracts were
5 combined and washed with water, dried over sodium sulfate, and concentrated in vacuo. Crystallization of the resulting solid from ethyl acetate/hexane provided 8.8 g of the desired title intermediate, m.p. 179-182°C. NMR, MS.

10 Analysis for $C_{11}H_{12}O_2S$:
 Calc.: C, 63.43; H, 5.81;
 Found: C, 63.18; H, 6.10.

Examples 2-14

15 The following compounds were prepared from the corresponding methyl esters according to the procedure of Example 1G. The general preparation of the ester intermediates followed that of Examples 1A, 1B, and a
20 variation of 1F wherein 90% formic acid was employed in place of the hydrogen chloride/methanol combination. 2-Monomethyl derivatives were prepared according to the procedure of Example 1A using allyl bromide in place of
3-chloro-2-methylpropene followed by subsequent trans-
25 formations in the same way. Yields are expressed as the molar percent yield from the ester except as indicated.

2. 2,2-Dimethyl-2,3-dihydrobenzofuran-7-carboxylic acid, 82% yield (from the 2-methyl-2-propenyloxy intermediate), m.p. 135-137°C. NMR, MS.

Analysis for $C_{11}H_{12}O_3$:

5 Calc.: C, 68.74; H, 6.29;

 Found: C, 69.04; H, 6.47.

3. 2,2-Dimethyl-4-chloro-2,3-dihydrobenzofuran-7-carboxylic acid, 87% yield, m.p. 195-197°C.

Analysis for $C_{11}H_{11}ClO_3$:

10 Calc.: C, 58.29; H, 4.89;

 Found: C, 58.55; H, 4.76.

4. 2,2-Dimethyl-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid, 71% yield (from the 2-methyl-2-propenylphenol intermediate), m.p. 158.5-160°C. NMR, MS.

15 Analysis for $C_{11}H_{11}ClO_3$:

 Calc.: C, 58.29; H, 4.89;

 Found: C, 58.08; H, 4.65.

5. 2,2-Dimethyl-2,3-dihydrobenzofuran-5-carboxylic acid, 61% yield, m.p. 174-176°C. NMR, MS.

20 Analysis for $C_{11}H_{12}O_3$:

 Calc.: C, 68.74; H, 6.29;

 Found: C, 68.51; H, 6.34.

6. 2,2,5-Trimethyl-2,3-dihydrobenzofuran-7-carboxylic acid, 82% yield, m.p. 170-172°C. NMR, MS.

25 Analysis for $C_{12}H_{14}O_3$:

 Calc.: C, 69.89; H, 6.84;

 Found: C, 70.19; H, 6.89.

7. 2,2-Dimethyl-2,3-dihydrobenzofuran-4-carboxylic acid, 66% yield (from the 2-methyl-2-propenylphenol intermediate), m.p. 174-176°C. MS, NMR.

Analysis for $C_{11}H_{12}O_3$:

5 Calc.: C, 68.74; H, 6.29;

 Found: C, 68.89; H, 6.25.

8. 2,2-Dimethyl-2,3-dihydrobenzofuran-6-carboxylic acid, 80% yield, m.p. 138-141°C. NMR, MS.

Analysis for $C_{11}H_{12}O_3$:

10 Calc.: C, 68.74; H, 6.29;

 Found: C, 68.50; H, 6.08.

9. 2-Methyl-5-methoxy-2,3-dihydrobenzofuran-7-carboxylic acid, 100% yield (from the 2-allylphenol intermediate via the bromo intermediate), m.p.

15 120-121°C.

Analysis for $C_{11}H_{12}O_4$:

 Calc.: C, 63.45; H, 5.81;

 Found: C, 63.22; H, 5.87.

20 10. 2,2-Dimethyl-7-chloro-2,3-dihydrobenzofuran-5-carboxylic acid, 72% yield, m.p. 189-190°C.

Analysis for $C_{11}H_{11}ClO_3$:

 Calc.: C, 58.29; H, 4.89;

 Found: C, 58.40; H, 4.93.

25 11. 2-Methyl-5-fluoro-2,3-dihydrobenzofuran-7-carboxylic acid, 72% yield, m.p. 129.5-131.5°C.

Analysis for $C_{10}H_9FO_3$:

 Calc.: C, 61.23; H, 4.62;

 Found: C, 61.41; H, 4.78.

12. 2-Methyl-2,3-dihydrobenzofuran-7-carboxylic acid, 88% yield (from the 2-(2-bromopropyl)phenol intermediate), m.p. 125-127°C.

Analysis for $C_{10}H_{10}O_3$:

5 Calc.: C, 67.03; H, 6.19;

 Found: C, 67.23; H, 5.99.

13. 2-Methyl-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid, 21% yield (from the 2-(2-bromopropyl)phenol intermediate), m.p. 184-188°C.

10 Analysis for $C_{10}H_9ClO_3$:

 Calc.: C, 56.49; H, 4.27;

 Found: C, 56.56; H, 4.38.

14. 2,2-Dimethyl-5-methoxy-2,3-dihydrobenzofuran-7-carboxylic acid, 68% yield, m.p. 140-142°C.

15 Analysis for $C_{12}H_{14}O_4$:

 Calc.: C, 64.85; H, 6.35;

 Found: C, 64.99; H, 6.25.

Example 15

20

2,2-Dimethylchroman-8-carboxylic acid

A. Preparation of 2-(3-methyl-3-hydroxybutyl)phenol.

25 To a solution of 200 ml of 3M methyl magnesium chloride in tetrahydrofuran (THF) and 150 ml of THF was added a solution 44.4 g of dihydrocoumarin in THF over a 40 minute period. An additional 150 ml of THF were added and, after cooling the resulting exotherm, the

mixture was stirred at room temperature overnight. The solution was cooled and treated with 50 ml of a saturated ammonium chloride solution and 100 ml of water. After stirring one hour, the mixture was added
5 to ice water and extracted with diethyl ether. The organic layer was washed with water, dried over sodium sulfate, and concentrated in vacuo to provide 57.5 g of the desired subtitle intermediate, m.p. 113-115°C.

B. Preparation of 2,2-dimethylchroman.

10 The 57.5 g of phenol from Example 15A above were dissolved in 320 ml of acetic acid and 120 ml of 20% sulfuric acid and heated to reflux for 45 minutes. The solution was cooled, added to ice, and extracted
15 with diethyl ether. The organic layer was washed with 200 ml of 10% sodium hydroxide and water, dried over sodium sulfate, and concentrated in vacuo. Vacuum distillation at 83-85°C. and approximately 5 torr provided 36.3 g of the desired subtitle intermediate.

C. Preparation of 2,2-dimethylchroman-8-carboxylic
20 acid.

To a solution of 1.6M n-butyllithium in hexane and 150 ml of diethyl ether were added a solution of 27 g of 2,2-dimethylchroman in diethyl
25 ether over a one hour period at room temperature. The solution was then heated at reflux 160 minutes, cooled, and poured into dry ice/diethyl ether. The mixture was allowed to come to room temperature, poured into ice water, and layers separated. The organic layer was

washed with water, dried over sodium sulfate, and concentrated in vacuo to provide 21 g of solid. The aqueous layer was acidified and the resulting precipitate extracted into diethyl ether/ethyl acetate. The organic
5 extract was washed with water, dried over sodium sulfate, and concentrated in vacuo to provide 9 g of solid. The two isolated solids were combined and chromatographed over silica gel eluting with 10% ethyl acetate in toluene. The appropriate fractions were combined and
10 concentrated in vacuo to provide 9.8 g of the desired title intermediate, m.p. 90-92°C.

Analysis for $C_{12}H_{14}O_3$:

Calc.: C, 69.89; H, 6.84;

Found: C, 69.84; H, 7.12.

15

Example 16

20

Endo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)benzo[b]thiophene-7-carboxamide (Z)-2-butenedioate.

25

A mixture of 8.8 g of 2,2-dimethyl-2,3-dihydrobenzothiophene-7-carboxylic acid and 119 g of thionyl chloride was heated at reflux for 3 hours. After the mixture was concentrated in vacuo and azeotroped with toluene, dry toluene was added and the solution cooled to 5°C. A solution of 7 g of tropamine

in toluene was added in dropwise fashion and the reaction heated at reflux overnight. After cooling, the mixture was added to ice water, made basic, and extracted with diethyl ether/ethyl acetate. The organic layer
5 was washed twice with 6N hydrochloric acid. The combined aqueous extracts were cooled, made basic with sodium hydroxide solution, and extracted with ethyl acetate. The ethyl acetate solution was washed twice with water, dried over sodium sulfate, and concentrated
10 in vacuo providing 11.6 g of the title product free base as an oil. The maleate salt was then prepared and crystallized from ethanol/diethyl ether/ethyl acetate providing 11.5 g of the desired title product, m.p. 197-199°C. NMR, MS.

15 Analysis for $C_{23}H_{30}N_2O_5S$:
 Calc.: C, 61.86; H, 6.77; N, 6.27;
 Found: C, 61.58; H, 6.84; N, 6.10.

20 Examples 17-42

The following products were prepared from the corresponding carboxylic acid via the acid chloride according to the procedure of Example 16 employing the appropriate amine or alcohol derivative of tropane.

25 17. Endo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 61% yield, m.p. 163-164°C.

Analysis for $C_{23}H_{30}N_2O_6$:

Calc.: C, 64.17; H, 7.02; N, 6.51;

Found: C, 64.20; H, 7.25; N, 6.29.

- 5 18. Endo-4-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 100% yield, m.p. 198-200°C.

Analysis for $C_{23}H_{29}ClN_2O_6$:

Calc.: C, 59.42; H, 6.29; N, 6.03;

Found: C, 59.58; H, 6.38; N, 6.23.

- 10 19. Endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 74% yield, m.p. 184-186°C.

Analysis for $C_{23}H_{29}ClN_2O_6$:

Calc.: C, 59.42; H, 6.29; N, 6.03;

- 15 Found: C, 59.23; H, 6.18; N, 6.14.

20. Endo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-5-benzofurancarboxamide (Z)-2-butenedioate, 83% yield, m.p. 193-195°C.

Analysis for $C_{23}H_{30}N_2O_6$:

- 20 Calc.: C, 64.17; H, 7.02; N, 6.51;

Found: C, 63.89; H, 6.85; N, 6.42.

21. Endo-2,3-dihydro-2,2,5-trimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 65% yield, m.p. 173-174°C.

- 25 Analysis for $C_{24}H_{32}N_2O_6$:

Calc.: C, 64.85; H, 7.26; N, 6.03;

Found: C, 64.59; H, 7.41; N, 6.29.

22. Endo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-4-benzofurancarboxamide (Z)-2-butenedioate, 27% yield, m.p. 182-184°C.

Analysis for $C_{23}H_{30}N_2O_6$:

5 Calc.: C, 64.17; H, 7.03; N, 6.51;

 Found: C, 63.95; H, 6.80; N, 6.72.

23. Endo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-6-benzofurancarboxamide (Z)-2-butenedioate, 43% yield, m.p. 174-176°C.

10 Analysis for $C_{23}H_{30}N_2O_6$:

 Calc.: C, 64.17; H, 7.02; N, 6.51;

 Found: C, 64.11; H, 6.97; N, 6.52.

15 24. Endo-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 51% yield, m.p. 174-176°C.

 Analysis for $C_{23}H_{29}NO_7$:

 Calc.: C, 64.02; H, 6.77; N, 3.25;

 Found: C, 64.02; H, 6.79; N, 3.21.

20 25. Endo-5-chloro-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 48% yield, m.p. 175-177°C.

 Analysis for $C_{23}H_{28}ClNO_7$:

25 Calc.: C, 59.29; H, 6.06; N, 3.01;

 Found: C, 59.19; H, 6.15; N, 2.93.

26. Exo-2,2-dimethyl-5-chloro-2,3-dihydro-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]-oct-3-yl ester (Z)-2-butenedioate, 86% yield, m.p. 222-224°C.

5 Analysis for $C_{23}H_{28}ClNO_7$:

Calc.: C, 59.29; H, 6.06; N, 3.01;

Found: C, 59.42; H, 5.88; N, 2.81.

27. dl-endo-2,3-dihydro-5-methoxy-2-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 62% yield, m.p. 172-174°C.

10

Analysis for $C_{23}H_{30}N_2O_7$:

Calc.: C, 61.87; H, 6.77; N, 6.27;

Found: C, 61.62; H, 6.81; N, 6.10.

28. dl-endo-2-methyl-5-methoxy-2,3-dihydro-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]-oct-3-yl ester (Z)-2-butenedioate, 22% yield, m.p. 162-164°C.

15

Analysis for $C_{23}H_{29}NO_8$:

Calc.: C, 61.73; H, 6.53; N, 3.13;

Found: C, 61.45; H, 6.68; N, 3.35.

29. Endo-2,2-dimethyl-7-chloro-2,3-dihydro-5-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]-oct-3-yl ester (Z)-2-butenedioate, 20% yield, m.p. 154-156°C.

20

25 Analysis for $C_{23}H_{28}ClNO_7$:

Calc.: C, 59.29; H, 6.06; N, 3.01;

Found: C, 59.06; H, 6.31; N, 2.95.

30. Exo-2,2-dimethyl-5-chloro-2,3-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 63% yield, m.p. 129-120.5°C.

5 Analysis for $C_{23}H_{29}ClN_2O_6$:

Calc.: C, 58.28; H, 6.38; N, 5.91;

Found: C, 58.65; H, 6.62; N, 5.72.

31. dl-endo-5-fluoro-2,3-dihydro-2-methyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 24% yield, m.p. 154-156°C.

10 Analysis for $C_{22}H_{26}FNO_7$:

Calc.: C, 60.68; H, 6.02; N, 3.22;

Found: C, 60.94; H, 6.21; N, 3.30.

15 32. dl-endo-5-chloro-2,3-dihydro-2-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 31% yield, m.p. 196-198°C.

Analysis for $C_{22}H_{27}ClN_2O_6$:

Calc.: C, 58.60; H, 6.04; N, 6.21;

20 Found: C, 58.88; H, 6.26; N, 6.17.

33. dl-endo-2,3-dihydro-2-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 43% yield, m.p. 144-146°C.

Analysis for $C_{22}H_{28}N_2O_6$:

25 Calc.: C, 63.45; H, 6.78; N, 6.73;

Found: C, 63.72; H, 7.00; N, 6.75.

34. dl-endo-5-chloro-2,3-dihydro-2-methyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 18% yield, m.p. 170-172°C.

5 Analysis for $C_{22}H_{26}ClNO_7$:

Calc.: C, 58.47; H, 5.80; N, 3.10;

Found: C, 58.93; H, 6.02; N, 3.28.

35. dl-endo-2,3-dihydro-2-methyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 36% yield, m.p. 178-179°C.

10

Analysis for $C_{22}H_{27}NO_7$:

Calc.: C, 63.30; H, 6.52; N, 3.36;

Found: C, 63.40; H, 6.76; N, 3.60.

36. Endo-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-8-chromancarboxamide (Z)-2-butenedioate, 39% yield, m.p. 172-174°C.

15

Analysis for $C_{24}H_{32}N_2O_6$:

Calc.: C, 64.85; H, 7.26; N, 6.30;

Found: C, 64.62; H, 7.24; N, 6.22.

37. Endo-2,3-dihydro-2,2,5-trimethyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 36% yield, m.p. 167-168°C.

20

Analysis for $C_{24}H_{31}NO_7$:

Calc.: C, 64.70; H, 7.01; N, 3.14;

Found: C, 64.46; H, 6.74; N, 2.95.

25

38. dl-exo-2,3-dihydro-2-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 48% yield, m.p. 134-135°C.

Analysis for $C_{22}H_{28}N_2O_6$:

5 Calc.: C, 63.45; H, 6.78; N, 6.73;

 Found: C, 63.15; H, 6.53; N, 6.47.

39. Exo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 42% yield, m.p. 171-173°C.

10 Analysis for $C_{23}H_{30}N_2O_6$:

 Calc.: C, 64.17; H, 7.02; N, 6.51;

 Found: C, 64.49; H, 7.10; N, 6.69.

15 40. dl-endo-2,3-dihydro-2,5-dimethyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (Z)-2-butenedioate, 6% yield, m.p. 161-164°C.

 Analysis for $C_{23}H_{29}NO_7$:

 Calc.: C, 64.02; H, 6.77; N, 3.28;

 Found: C, 64.24; H, 6.54; N, 3.52.

20 41. Endo-2,3-dihydro-2,2-dimethyl-5-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 65% yield, m.p. 189-190°C.

 Analysis for $C_{24}H_{32}N_2O_7$:

25 Calc.: C, 62.59; H, 7.00; N, 6.08;

 Found: C, 62.30; H, 7.17; N, 6.03.

42. Endo-5-fluoro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 50% yield, m.p. 178-180°C.

Analysis for $C_{23}H_{29}FN_2O_6$:

5 Calc.: C, 61.60; H, 6.52; N, 6.25;
 Found: C, 61.31; H, 6.77; N, 6.15.

Examples 43-46

10 The following intermediates were prepared in the same manner as described for Examples 2-14.

43. 2,2-Dimethyl-2,3-dihydro-6-chlorobenzofuran-7-carboxylic acid, 58% yield, m.p. 164-166°C.

Analysis for $C_{11}H_{11}ClO_3$:

15 Calc.: C, 58.29; H, 4.89;
 Found: C, 58.15; H, 4.92.

44. 4-Amino-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid, 71% yield (from the N-formyl derivative of the methyl ester), m.p. 166-169°C.

Analysis for $C_{11}H_{13}NO_3$:

20 Calc.: C, 63.76; H, 6.32; N, 6.76;
 Found: C, 63.48; H, 6.55; N, 6.85.

45. 2,2-Dimethyl-4-methoxy-2,3-dihydrobenzofuran-7-carboxylic acid, 69% yield, m.p. 174-175°C.

Analysis for $C_{12}H_{14}O_4$:

25 Calc.: C, 64.85; H, 6.35;
 Found: C, 64.77; H, 6.19.

46. 2,3-Dihydro-2,2-dimethyl-6-fluoro-7-benzofurancarboxylic acid, 74% yield, m.p. 143-145°C.

Analysis for $C_{11}H_{11}FO_3$:

Calc.: C, 62.85; H, 5.27;

5 Found: C, 62.87; H, 5.13.

Example 47

5-Amino-4-chloro-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylic acid

10 A. Preparation of 4-chloro-5-nitro-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylic acid.

To a mixture of 40 ml of nitric acid and 40 ml of sulfuric acid cooled to 5°C. by means of an external ice bath were added 10 g of 4-chloro-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylic acid over a period of 28 minutes. After stirring at 5°C. for 15 10 minutes, the mixture was added to ice with stirring. The resulting solid was collected by filtration and washed with water. After air drying, the residue was crystallized twice from ethyl acetate/hexane to provide 20 3.5 g of the desired subtitle intermediate, m.p. 260-262°C.

Analysis for $C_{11}H_{10}ClNO_5$:

Calc.: C, 48.64; H, 3.71; N, 5.16;

Found: C, 48.36; H, 3.81; N, 5.30.

B. Preparation of 5-amino-4-chloro-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylic acid.

A mixture of 7.53 g of the nitro intermediate named in Example 47A above in 150 ml of ethyl acetate was subjected to a hydrogen atmosphere for 16 hours in the presence of 5% palladium on carbon. The reaction mixture was filtered and the filtrate concentrated to give a residue which was crystallized from ethyl acetate/hexane providing 5.1 g of the desired title intermediate, m.p. 185-187°C.

Analysis for $C_{11}H_{10}ClNO_3$:

Calc.: C, 55.13; H, 4.21; N, 5.84;

Found: C, 54.91; H, 4.50; N, 5.61.

Example 48

15 5-Chloro-4-methoxy-2,2-dimethyl-2,3-dihydro-7-benzofuran-carboxylic acid

A mixture of methyl 4-methoxy-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylate, 7.1 g of pyridine, and 400 ml of tetrahydrofuran was cooled to -30°C by means of an external dry ice/acetone bath. A solution of 27.5 g of iodobenzene dichloride in 100 ml of dry tetrahydrofuran was added dropwise to the mixture. After addition was complete, the reaction was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo, water was added, and the mixture was steam distilled. To the residue were added ethyl acetate and diethyl ether. The organic mixture

was washed with water, dried over sodium sulfate, and concentrated in vacuo. Eleven grams of this product were treated with 15 g of sodium hydroxide and 200 ml of water following the procedure of Example 1G above to provide 7.6 g of the desired title intermediate, m.p. 165-166.5°C.

Analysis for $C_{12}H_{13}ClO_4$:

Calc.: C, 56.15; H, 5.11;

Found: C, 56.04; H, 5.21.

Following the same procedure, 19.9 g of methyl 4-amino-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylate was transformed into 20.1 g of 4-amino-5-chloro-2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylic acid, m.p. 176-178°C.

Analysis for $C_{11}H_{12}ClNO_3$:

Calc.: C, 54.67; H, 5.01; N, 5.80;

Found: C, 54.43; H, 5.22; N, 5.74.

Examples 49-58

The following compounds were prepared from the corresponding carboxylic acid and the appropriate amine via the acid chloride prepared from the thionyl chloride according to the procedure of Example 16 or as generated upon treatment with phosphorous trichloride.

49. 2,3-Dihydro-5-chloro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 75% yield, m.p. 195-197°C.

Analysis for $C_{22}H_{27}ClN_2O_6$:

Calc.: C, 58.60; H, 6.04; N, 6.21;

Found: C, 58.46; H, 6.01; N, 6.20.

50. Endo-2,2-dimethyl-2,3-dihydro-6-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofuran-carboxamide (Z)-2-butenedioate, 70% yield, m.p. 198.5-200°C.

5 Analysis for $C_{23}H_{29}ClN_2O_6$:

Calc.: C, 59.42; H, 6.29; N, 6.03;

Found: C, 59.16; H, 6.24; N, 5.96.

51. Endo-7-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-5-benzofuran-carboxamide (Z)-2-butenedioate, 79% yield, m.p. 194-196°C.

Analysis for $C_{22}H_{29}ClN_2O_6$:

Calc.: C, 59.42; H, 6.29; N, 6.03;

Found: C, 59.48; H, 6.23; N, 6.00.

15 52. Endo-2,3-dihydro-4-methoxy-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofuran-carboxamide (Z)-2-butenedioate, 50% yield, m.p. 194-195°C.

Analysis for $C_{24}H_{32}N_2O_7$:

Calc.: C, 62.59; H, 7.00; N, 6.08;

20 Found: C, 62.80; H, 7.11; N, 6.09.

53. N-(1-azabicyclo[2.2.2]oct-3-yl)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-8-carboxamide (Z)-2-butenedioate, 36% yield, m.p. 169-170°C.

Analysis $C_{22}H_{30}N_2O_6$:

25 Calc.: C, 64.17; H, 7.02; N, 6.51;

Found: C, 64.00; H, 7.03; N, 6.46.

54. Endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 20% yield, m.p. 175-177°C.

Analysis for $C_{24}H_{31}ClN_2O_6$:

5 Calc.: C, 60.18; H, 6.52; N, 5.84;

Found: C, 60.42; H, 6.75; N, 6.03.

55. Endo-2,3-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 36% yield, m.p. 153-154°C.

10 Analysis for $C_{24}H_{32}N_2O_6$:

Calc.: C, 65.48; H, 7.47; N, 6.11;

Found: C, 65.25; H, 7.24; N, 6.01.

15 56. Endo-2,3-dihydro-4-amino-5-chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 45% yield, m.p. 211-213°C.

Analysis for $C_{23}H_{30}ClN_3O_6$:

Calc.: C, 57.56; H, 6.30; N, 8.76;

Found: C, 57.42; H, 6.28; N, 8.63.

20 57. Endo-5-chloro-2,3-dihydro-4-methoxy-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 49% yield, m.p. 179-180°C.

Analysis for $C_{24}H_{31}ClN_2O_7$:

25 Calc.: C, 58.24; H, 6.31; N, 5.66;

Found: C, 57.96; H, 6.48; N, 5.78.

58. 5-Fluoro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 50% yield, m.p. 178-180°C.

Analysis for $C_{23}H_{29}FN_2O_6$:

5 Calc.: C, 61.60; H, 6.52; N, 6.25;
 Found: C, 61.31; H, 6.77; N, 6.15.

Example 59

Endo-5-[(dimethylamino)sulfonyl]-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate

10 A. Preparation of 5-[(dimethylamino)sulfonyl]-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid.

 Fifty-eight grams of chlorosulfonic acid was cooled to 10°C. and a solution of 19.2 g of 2,2-dimethyl-2,3-dihydro-7-benzofurancarboxylic acid in 300 ml of methylene chloride was added slowly keeping the temperature between 10-15°C. When the addition was complete, the mixture was stirred in the ice bath for two hours. The mixture was added to ice water and the resulting white precipitate recovered by filtration. The solid was added to approximately 200 ml of 40% dimethylamine in water which had been cooled to 10°C. After stirring overnight, the mixture was acidified with 6N hydrochloric acid. The resulting white precipitate was recovered by filtration. The residue was crystallized from ethyl acetate/hexane to provide 5.7 g of the desired subtitle intermediate, m.p. 211-212°C.

Analysis for $C_{13}H_{17}NSO_5$:

Calc.: C, 52.16; H, 5.72; N, 4.68;

Found: C, 52.44; H, 5.79; N, 4.64.

5 B. Preparation of endo-5-[(dimethylamino)sulfonyl]-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate.

10 The 5.7 g of the benzofurancarboxylic acid of Example 59A above was transformed into the acid chloride and reacted with tropamine according to the procedure of Example 16 to provide 7.0 g of the desired title product, m.p. 202-203°C.

Analysis for $C_{25}H_{35}N_3SO_8$:

Calc.: C, 55.85; H, 6.56; N, 7.82;

Found: C, 55.93; H, 6.56; N, 7.65.

15

Example 60

2,3-Dihydro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate

20 A mixture of 2.4 g of 2,3-dihydro-5-chloro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide, 0.51 g of triethylamine, 0.3 g of 5% palladium on carbon, and 100 ml of ethanol were hydrogenated at 60 psi and 40-50°C. overnight. The mixture was cooled, filtered, concentrated in vacuo, and converted into the maleate salt. Crystallization from
25 ethanol/diethyl ether provided 2.0 g of desired title product, m.p. 182-185°C.

Analysis for $C_{22}H_{28}N_2O_6$:

Calc.: C, 63.45; H, 6.78; N, 6.73;

Found: C, 63.58; H, 6.91; N, 6.86.

Example 61

Endo-2,2-dimethyl-6-chloro-N-(8-methyl-8-azabicyclo-
[3.2.1]oct-3-yl)-8-chromancarboxamide (Z)-2-butenedioate

Following the general procedure of Example
5 48, 1.96 of endo-2,2-dimethyl-N-(8-methyl-8-azabicyclo-
[3.2.1]oct-3-yl)-8-chromancarboxamide (Z)-butenedioate
50 ml of chloroform, 1.02 ml of pyridine, and 1.24 g of
iodobenzene dichloride were allowed to react. After
workup and crystallization from ethanol/diethyl acetate,
10 350 mg of the desired title product were isolated, m.p.
210-211°C.

Analysis for $C_{24}H_{31}ClN_2O_6$:

Calc.: C, 60.18; H, 6.52; N, 5.85;

Found: C, 59.94; H, 6.47; N, 5.75.

15

Example 62

Endo-2,3-dihydro-5-hydroxy-2,2-dimethyl-N-(8-methyl-8-aza-
bicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-
butenedioate

A mixture of 1.4 g of endo-2,3-dihydro-5-
20 methoxy-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-
3-yl)-7-benzofurancarboxamide and 11.5 g of pyridine
hydrochloride was heated under a nitrogen atmosphere
at 180°C. for three hours. The molten mixture was
poured hot over ice and stirred overnight. The
25 solution was made basic with sodium hydroxide,
extracted with ethyl acetate, and carbon dioxide gas
was bubbled into the basic solution to adjust the pH.

Extraction with ethyl acetate and concentration of the organic solution provided a residue which was converted into the maleate salt. After crystallization from ethanol/diethyl ether, the title product (114 mg) was
5 isolated, m.p. 228-231°C.

Analysis for $C_{23}H_{30}N_2O_7$:

Calc.: C, 61.87; H, 6.77; N, 6.27;

Found: C, 61.67; H, 7.00; N, 6.21.

Example 63

10 The following benzyl derivatives were prepared from the corresponding acid chloride and the appropriate 8-benzyl-tropanamine derivative. These compounds are useful as intermediates in that they may be deblocked (see Example 64 which follows) and
15 alkylated with the appropriate alkylating agent to prepare the compounds of this invention. (See Example 65).

Endo-2,3-dihydro-2-methyl-N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-
20 butenedioate, 70% yield, m.p. 183-184°C.

Analysis for $C_{28}H_{32}N_2O_6$:

Calc.: C, 68.28; H, 6.55; N, 5.69;

Found: C, 67.98; H, 6.54; N, 5.39.

Endo-2,3-dihydro-2,2-dimethyl-N-(8-benzyl-8-
25 azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 49% yield, m.p. 186-187°C.

Analysis for $C_{29}H_{34}N_2O_6$:

Calc.: C, 68.76; H, 6.77; N, 5.53;

Found: C, 68.97; H, 6.94; N, 5.63.

Endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide, 59% yield.

Analysis for $C_{25}H_{29}ClN_2O_2$:

5 Calc.: C, 70.66; H, 6.88; N, 6.59;

 Found: C, 70.39; H, 7.00; N, 6.43.

Exo-2-methyl-2,3-dihydro-N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 82%, m.p. 125-127°C.

10 Analysis for $C_{28}H_{32}N_2O_6$:

 Calc.: C, 68.28; H, 6.55; N, 5.67;

 Found: C, 68.00; H, 6.61; N, 5.47.

Exo-2,2-dimethyl-2,3-dihydro-N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 83% yield, m.p. 208.5-210°C.

15

 Analysis for $C_{29}H_{34}N_2O_6$:

 Calc.: C, 68.76; H, 6.77; N, 5.53;

 Found: C, 68.74; H, 7.03; N, 5.68.

Example 64

20 Endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate

 A mixture of 3.4 g of 5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide, 2.0 g of 10% palladium on carbon, 0.7 ml of concentrated hydrochloric acid, and 200 ml of acetic acid were subjected to hydrogenation at a temperature of approximately 25-30°C. After hydrogen

25

uptake ceased, the reaction mixture was filtered, and the filtrate concentrated in vacuo. One gram of the residue was purified by high pressure liquid chromatography using 24% ethanol and 1% ammonium hydroxide in ethyl acetate as the eluant. The desired fractions were combined, concentrated in vacuo, and converted into the maleate salt. Recrystallization from ethanol/diethyl ether provided 623 mg of the desired title intermediate, m.p. 210-212°C.

10

Analysis for $C_{22}H_{27}ClN_2O_6$:

Calc.: C, 58.60; H, 6.04; N, 6.21;

Found: C, 58.89; H, 6.14; N, 6.42.

Example 65

15

The debenzylated intermediate of Example 64 can be converted into the desired N-alkyl derivative of this invention by treating the intermediate with the appropriate (C_1 - C_3) alkyl iodide in tetrahydrofuran or isopropyl alcohol in the presence of sodium carbonate.

20

Example 66

5-Bromo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid

25

The title intermediate was prepared in 20% yield from 2-methyl-2-propenyl 5-bromo-3-(2-methyl-2-propenyl)-2-hydroxybenzoate upon heating at reflux with 90% formic acid.

Analysis for $C_{11}H_{11}BrO_3$:

Calc.: C, 48.73; H, 4.09;

Found: C, 48.73; H, 4.13.

5

Examples 67-69

The following compounds were prepared from the corresponding benzofurancarboxylic acids and the appropriate amine following the procedure of Example 16.

10 67. Endo-5-bromo-2,2-dimethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 16% yield, m.p. 185-187°C.

Analysis for $C_{23}H_{29}BrN_2O_6$:

Calc.: C, 54.23; H, 5.74; N, 5.50;

Found: C, 54.22; H, 5.79; N, 5.47.

15

68. 2,2-Dimethyl-2,3-dihydro-5-fluoro-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 31% yield, m.p. 199-200°C.

Analysis for $C_{22}H_{27}FN_2O_6$:

Calc.: C, 60.82; H, 6.26; N, 6.45;

20

Found: C, 61.07; H, 6.22; N, 6.34.

69. Endo-5-fluoro-2,3-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate, 16% yield, m.p. 111-112°C.

Analysis for $C_{24}H_{31}FN_2O_6$:

25

Calc.: C, 62.33; H, 6.76; N, 6.06;

Found: C, 62.28; H, 6.70; N, 5.85.

Other compounds illustrative of this invention include:

5 Endo-5-methylthio-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofuran-carboxamide

Endo-5-methylsulfonyl-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofuran-carboxamide

10 Endo-5-methylsulfinyl-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofuran-carboxamide

5-Methylthio-2,3-dihydro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide

15 5-Methylsulfinyl-2,3-dihydro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide

5-Methylsulfonyl-2,3-dihydro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-benzofurancarboxamide

20 Endo-5-methylthio-2,3-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-7-benzofuran-carboxamide

Endo-5-methylsulfinyl-2,3-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-7-benzofuran-carboxamide

25 Endo-5-methylsulfonyl-2,3-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-7-benzofuran-carboxamide

6-Chloro-3,4-dihydro-2,2-diethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-2H-1-benzopyran-8-carboxamide

3,4-Dihydro-2,2-diethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-2H-1-benzopyran-8-carboxamide

5 Endo-6-chloro-3,4-dihydro-2,2-diethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2H-1-benzopyran-8-carboxamide

Endo-3,4-dihydro-2,2-diethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2H-1-benzopyran-8-carboxamide

10 Endo-6-chloro-3,4-dihydro-2,2-diethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2H-1-benzopyran-8-carboxamide

Endo-3,4-dihydro-2,2-diethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2H-1-benzopyran-8-carboxamide

15 6-Fluoro-3,4-dihydro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-2H-1-benzopyran-8-carboxamide

6-Chloro-3,4-dihydro-2,2-dimethyl-N-(1-azabicyclo[2.2.2]oct-3-yl)-2H-1-benzopyran-8-carboxamide

20 Endo-6-fluoro-3,4-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2H-1-benzopyran-8-carboxamide

Endo-6-chloro-3,4-dihydro-2,2-dimethyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2H-1-benzopyran-8-carboxamide

Endo-6-fluoro-3,4-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2H-1-benzopyran-8-carboxamide

5 According to another aspect of this invention there is provided the use of compounds of Formula I, or a pharmaceutically acceptable salt thereof, in treating a mammal suffering from migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in a mammal which comprises administering to said mammal an effective
10 amount of a compound of Formula I.

The compounds of Formula I of this invention are long-acting, orally effective specific 5-HT₃ receptor antagonists, rendering them useful for the treatment of migraine. Because of this mechanism, the compounds
15 of this invention should also be useful for treating emesis, motion sickness, ischemic bowel disease, diabetic gastric paresis, relaxation of the gastrointestinal tract for instrumentation, other gastrointestinal pain following surgery, obstetrics or as in
20 abdominal cramps, and for treating CNS disorders such as schizophrenia and anxiety. The ability of these compounds to antagonize the effects of 5-HT was assessed by their inhibition of the Von Bezold-Jarisch reflex induced by 5-HT injected intravenously into the rat (See
25 Paintal, Physiol. Rev., 53, 159 (1973)). When administered by the intravenous route 15 minutes prior to the administration of 5-HT, the compounds of this invention were effective in inhibiting the serotonin-induced Bezold-Jarisch reflex as summarized in Table 1 below:

Table 1

Inhibition of Serotonin-induced Bezold-Jarisch Reflex in Rats

5	Compound of Example No.	<u>Percent Inhibition of Reflex in Rats (mg/kg I.V.)</u>			
		<u>0.03</u>	<u>0.01</u>	<u>0.003</u>	<u>0.001</u>
	16		0.1		
10	17	82	53	-2	
	18		1.2		
	19			90	66
	20		16		
	21		87	11	0.3
15	22		-4		
	23		-8		
	24		38	21	
	25		83	19	10
	26		2		
20	27		20		
	28		4		
	29		-4		
	30		67	26	
	31		32		
25	32		80	80	58
	33	57	22		
	34		69	51	6
	35		31		
	36		76		4
30	37		4		
	38	51	26		
	39	82	53	-2	
	40		67	14	3

Table 1 Continued

Inhibition of Serotonin-induced Bezold-Jarisch Reflex in Rats

5

Percent Inhibition of Reflex in Rats (mg/kg I.V.)

Compound of Example No.	<u>0.03</u>	<u>0.01</u>	<u>0.003</u>	<u>0.001</u>
10				
41		-1		
49		89	40	
50		-3		
52			-7	
15				
53			93	50
54		94	84	
55			88	
56		89	25	
57		3		
20				
58		71		
60			87	25
61		91	30	
62		54		

25

These compounds may also be used as antiemetic agents. This use is exemplified by the compound of Example 19 which effectively blocked cisplatin-induced emesis in dogs with an i.v. ED₅₀ of 35.6 mcg/kg. Since 5HT₃ receptors are prevalent in the GI tract, other potential uses include other diseases of the gastrointestinal tract, such as ischemic

30

bowel, esophageal reflux, etc.

According to one further aspect of this invention there is provided a pharmaceutical formulation for blocking the M-receptors for 5-hydroxytryptamine comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with



one or more pharmaceutically acceptable carriers, diluents or excipients therefor.

The compounds of Formula I of this invention may be administered by various routes including the oral, rectal, transdermal, subcutaneous, intravenous, 5 intramuscular, or intranasal routes. The compounds are usually employed in the form of pharmaceutical compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least 10 one active compound. Accordingly, the invention includes a pharmaceutical composition comprising as active ingredient a compound of Formula I in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

15 In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier 20 serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, 25 solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.

30 Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose,

sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl-
5 and propyl-hydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the
10 invention may, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.

The compositions usually contain active
15 ingredient from about 1% to about 95% by weight and are preferably formulated in a unit dosage form, each dosage containing from about 0.5 to about 500 mg, more usually 1 to about 300 mg, of the active ingredient. The term
20 "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.

25 The active compounds are effective over a wide dosage range and typical dosages per day will normally fall within the range of about 0.020 to about 50 mg/kg of body weight. In the treatment of adult humans, a range of from about 0.020 to about 10 mg/kg, in single
30 or divided doses, is preferred. However, it will be

understood that the amount of the compound actually administered will be determined by a physician in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.

The following formulation examples may employ as active ingredients any of the pharmaceutical compounds of the invention. The examples are illustrative only and are not intended to limit the scope of the invention in any way.

Example 70

Hard gelatin capsules are prepared using the following ingredients:

Quantity (mg/capsule)

Endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide	
(Z)-2-butenedioate	250
Starch dried	200
Magnesium stearate	10

The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.

Example 71

5

A tablet formula is prepared using the ingredients below:

	<u>Quantity (mg/tablet)</u>
10	<u>d</u> -Endo-5-chloro-2,3-dihydro-2-ethyl-2-methyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]-oct-3-yl ester (Z)-2-butenedioate 250
	Cellulose, microcrystalline 400
15	Silicon dioxide, fumed 10
	Stearic acid 5

The components are blended and compressed to form tablets each weighing 665 mg.

20

Example 72

An aerosol solution is prepared containing the following components:

5

Weight %

1-2,3-dihydro-2-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide hydrochloride	0.25
Ethanol	29.75
Propellant 22 (Chlorodifluoromethane)	70.00

10

15

20

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remaining amount of propellant. The valve units are then fitted to the container.

Example 73

Tablets each containing 60 mg of active ingredient are made up as follows:

5	4-fluoro-2,3-dihydro-2,2-diethyl-7-benzofurancarboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester lactobionate	60 mg
10	Starch	45 mg
	Microcrystalline cellulose	35 mg
	Polyvinylpyrrolidone (as 10% solution in water)	4 mg
	Sodium carboxymethyl starch	4.5 mg
15	Magnesium stearate	0.5 mg
	Talc	1 mg
		--
	Total	150 mg

20 The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so
25 produced are dried at 50-60°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules

which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Example 74

5

Capsules each containing 80 mg of medicament are made as follows:

10	2,3-dihydro-2,2,5-trimethyl- N-(8-ethyl-8-azabicyclo[3.2.1]- oct-3-yl)-7-benzofurancarboxamide (Z)-2-butenedioate	80 mg
	Starch	59 mg
	Microcrystalline cellulose	59 mg
15	Magnesium stearate	2 mg
	Total	200 mg

20 The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Example 75

25

Suppositories each containing 225 mg of active ingredient are made as follows:

	Endo-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-5-benzothiophenecarboxamide	225 mg
5	Saturated fatty acid glycerides to	2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Example 76

15

Suspensions each containing 50 mg of medication per 5 ml dose are made as follows:


20	Endo-4-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-indolecarboxamide	50 mg
	Sodium carboxymethyl cellulose	50 mg
	Syrup	1.25 ml
25	Benzoic acid solution	0.10 ml
	Flavor	q.v.
	Color	q.v.
	Purified water to	5 ml

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethylcellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

CLAIMS

The claims defining the invention are as follows:

1. A compound of the Formula I



10 or a pharmaceutically acceptable salt thereof;

wherein:

15 R_a and R_b are independently ~~hydrogen~~, methyl, or ethyl, or when taken together with the carbon atom to which they are attached form a C_3-C_6 cycloalkyl ring; ~~provided that R_a and R_b may not both be hydrogen at the same time;~~

E is O, NH, or S;

20 R_1 and R_{1a} are independently hydrogen, methyl, halo, C_1-C_3 alkoxy, $(C_1-C_3 \text{ alkyl})-S(O)_t-$, trifluoromethyl, amino, hydroxy, $(CH_3)_2NSO_2-$, or $(C_1-C_4 \text{ alkyl})CONH-$;

m is 1 or 2;


t is 0, 1, or 2;

25 Z is O or NH; and




R_2 is quinuclidine, quinuclidine N-oxide,
1-azabicyclo[3.3.1]non-4-yl,

5


 $R_2 a$

10

 $R_2 b$

or

15

 $R_2 c$

wherein


20

R_3 is C_1 - C_3 alkyl, p and q are independently 0-2; Q is O or S; n is 0 or 1; one of R_4 and R_5 when n is 0 is C_1 - C_4 alkoxy, C_1 - C_4 alkoxy carbonyl, hydroxy, or C_1 - C_4 alkyl optionally substituted by hydroxy, C_1 - C_4 alkoxy, or C_1 - C_4 acyloxy and the other of R_4 and R_5 is hydrogen or C_1 - C_4 alkyl; one of R_4 , R_5 , and R_6 when n is 1 is C_1 - C_4 alkyl and the other two of R_4 , R_5 , and R_6 are independently hydrogen or C_1 - C_4 alkyl.

25

2. A compound of the formula

5



or a pharmaceutically acceptable salt thereof;

10

wherein:

R_a and R_b are independently ~~hydrogen~~, methyl, or ethyl, or when taken together with the carbon atom to which they are attached form a C_3 - C_6 cycloalkyl ring, ~~provided that R_a and R_b may not both be hydrogen at the same time;~~

20

E is O, NH, or S;


R_1 is hydrogen, methyl, fluoro, chloro, or methoxy;

m is 1 or 2;

Z is O or NH; and


R_2 is

25




$R_2 a$



R₂b

5

or


R₂c

10 wherein

R₃ is C₁-C₃ alkyl, p and q are independently 0-2; Q is O or S; n is 0 or 1; one of R₄ and R₅ when n is 0 is C₁-C₄ alkoxy, C₁-C₄ alkoxy carbonyl, hydroxy, or C₁-C₄ alkyl optionally substituted by hydroxy, C₁-C₄ alkoxy, or C₁-C₄ acyloxy and the other of R₄ and R₅ is hydrogen or C₁-C₄ alkyl; one of R₄, R₅, and R₆ when n is 1 is C₁-C₄ alkyl and the other two of R₄, R₅, and R₆ are independently hydrogen or C₁-C₄ alkyl.

20 formula

3. A compound of claim 1 which is of the



Ia

25

wherein


m is 1 or 2, R_1' is hydrogen, methyl, fluoro, bromo, or chloro, and R_2' is endo-8-methyl-8-azabicyclo-[3.2.1]oct-3-yl, 1-azabicyclo[2.2.2]-oct-3-yl, or endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl, or a pharmaceutically-acceptable salt thereof.

4. Endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo-[3.2.1]oct-3-yl)-7-benzofuran-carboxamide or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical formulation for blocking the M-receptors for 5-hydroxytryptamine comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, in association with one or more pharmaceutically acceptable carriers, diluents, excipients and/or adjuvants therefor.

6. A process for preparing a compound of the Formula I as claimed in any one of claims 1 to 4 which comprises:

(a) reacting a compound of the Formula II




wherein X is OH or a carboxylic acid activating group and R_1 , R_{1a} , R_a , R_b , E, and m are as defined in claim 1, with a compound of the Formula III



wherein Z and R_2 are as defined in claim 1, or


(b) hydrogenating a nitro compound of the Formula



wherein R_1 , R_2 , R_a , R_b , E, Z, and m are as defined above to give a compound of Formula I where R_{1a} is amino, or




(c) halogenating a compound of the Formula




where R_1 , R_2 , R_a , R_b , E , Z , and m are as defined above to provide a compound of Formula I where R_{1a} is halo, or

(d) reacting an alkoxy compound of the Formula




where R_1 , R_2 , R_a , R_b , E , Z , and m are as defined above, with dealkylating reagent to provide a compound of Formula I where R_{1a} is hydroxy, or

(e) reacting a compound of the Formula




where R_1 , R_2 , R_a , R_b , E , Z , and m are as defined above, with dimethylamine to provide a compound of Formula I where R_{1a} is $(CH_3)_2NSO_2-$, or

(f) reacting a compound of the Formula



where R_1 , R_{1a} , R_a , R_b , E , Z , and m are as defined above, and R_2 is R_{2a} , R_{2b} , or R_{2c} and R_3 is hydrogen, with a C_1 - C_3 alkyl halide, or

(g) reacting a compound of the Formula



where R_1 , R_2 , R_a , R_b , E , Z , and m are as defined above, with an oxidizing agent, and

(h) optionally converting the resulting product into a pharmaceutically acceptable salt.

7. A compound of the Formula I whenever prepared by a process according to claim 6.

8. A compound of the Formula Ia as defined in claim 3, whenever prepared by a process according to claim 6.

9. An azabicyclo benzothiophene-, benzofuran- or benzopyran-carboxamide or ester, as herein described with reference to any one of Examples 16 to 42, 49 to 62, 65 or 67 to 69.

10. A process for preparing an azabicyclo benzothiophene-, benzofuran- or benzopyran- carboxamide or ester, which process is substantially as herein described with reference to any one of Examples 16 to 42, 49 to 62, 65 or 67 to 69.

11. A pharmaceutical formulation for blocking M-receptors for 5-hydroxytryptamine, comprising a compound of claim 9, or a pharmaceutically acceptable salt thereof, in association with one or more pharmaceutically acceptable carriers, diluents, excipients and/or adjuvants.

12. A pharmaceutical formulation for blocking M-receptors for 5-hydroxytryptamine, which formulation is substantially as herein described with reference to any one of Examples 70 to 76.

13. A method of blocking M-receptors for 5-hydroxytryptamine in a mammal requiring blocking of said receptors, comprising administering to said mammal a compound of any one of claims 1 to 4, 7 to 9 or a formulation of any one of claims 5, 11 or 12 in an amount which effectively blocks said M-receptors for 5-hydroxytryptamine.



14. A method of treating migraine, emesis, gastrointestinal disorders, schizophrenia, and/or anxiety in a mammal requiring such treatment, comprising administering to said mammal a compound of any one of claims 1 to 4, 7 to 9 or a formulation of any one of claims 5, 11 or 12 in an amount which effectively blocks M-receptors for 5-hydroxytryptamine in said mammal.

DATED this TWENTY-FIRST day of JANUARY 1991

Eli Lilly and Company

Patent Attorneys for the Applicant
SPRUSON & FERGUSON

